Januvia

Januvia. It is a medication used for the treatment of type 2 diabetes and belongs to the class of drugs known as DPP-4 inhibitors. The active pharmaceutical ingredient is sitagliptin, which works by increasing the levels of incretin hormones to help control blood sugar. It is typically prescribed as an adjunct to diet and exercise and is often used in combination with other antidiabetic agents like metformin.

Medical uses

Januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other oral antihyperglycemic agents, such as metformin, a sulfonylurea like glimepiride, or a thiazolidinedione such as pioglitazone. Clinical trials, including studies presented at the American Diabetes Association scientific sessions, have demonstrated its efficacy in lowering hemoglobin A1c levels. It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

Adverse effects

Common adverse reactions include nasopharyngitis, headache, and upper respiratory tract infection. More serious but rare risks include severe joint pain, acute pancreatitis, and hypersensitivity reactions such as angioedema. Post-marketing reports have documented cases of bullous pemphigoid and a potential increased risk of heart failure, though large outcomes trials like TECOS did not show a significant increase in major adverse cardiovascular events. The U.S. Food and Drug Administration and the European Medicines Agency have issued safety communications regarding these risks.

Pharmacology

Sitagliptin is a potent, selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the concentration of active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This enhances glucose-dependent insulin secretion from the pancreatic beta cells and suppresses elevated glucagon secretion from the pancreatic alpha cells. The drug is rapidly absorbed after oral administration, with an absolute bioavailability of approximately 87%, and is primarily excreted unchanged by the kidneys via renal excretion.

History

Sitagliptin was discovered by scientists at Merck & Co. following research into DPP-4 inhibition as a novel approach to diabetes therapy. It received its first approval from the U.S. Food and Drug Administration in October 2006, becoming the first DPP-4 inhibitor marketed in the United States. Subsequent approvals were granted by the European Medicines Agency and other regulatory bodies worldwide. The development program included key clinical trials such as the JANUVIA trials, which were part of the submission to the FDA.

Society and culture

Januvia has been a significant commercial product for Merck & Co., generating billions in annual revenue and facing competition from other DPP-4 inhibitors like saxagliptin (Onglyza) and linagliptin (Tradjenta). It has been the subject of direct-to-consumer advertising campaigns in the United States. The drug's patent expiration has led to the introduction of generic versions in various markets. Cost and access have been discussed in the context of the broader pharmaceutical industry and healthcare systems like the National Health Service in the United Kingdom.

Category:Antidiabetic drugs Category:Merck & Co. brands Category:Dipeptidyl peptidase-4 inhibitors